CSS
TVRD

Cubist Systematic Strategies’s Tvardi Therapeutics TVRD Stock Holding History

Cubist Systematic Strategies’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,698
Closed -$103K – 4200
2023
Q3 		$103K Sell
1,698
-3,430
-67% -$322K ﹤0.01% 2936
2023
Q2 		$522K Buy
+5,128
New +$706K ﹤0.01% 2368
2022
Q3 		– Sell
-7,719
Closed -$2.54M – 4793
2022
Q2 		$2.54M Buy
7,719
+7,635
+9,089% +$2.68M 0.02% 1628
2022
Q1 		$37K Sell
84
-2,946
-97% -$1.21M ﹤0.01% 3421
2021
Q4 		$1.33M Buy
3,030
+2,509
+482% +$1.26M 0.01% 1693
2021
Q3 		$290K Buy
+521
New +$261K ﹤0.01% 2378
2021
Q2 		– Sell
-1,559
Closed -$1.22M – 3140
2021
Q1 		$1.22M Buy
1,559
+422
+37% +$289K 0.02% 1402
2020
Q4 		$619K Sell
1,137
-786
-41% -$412K 0.01% 1664
2020
Q3 		$881K Buy
1,923
+559
+41% +$325K 0.01% 1407
2020
Q2 		$840K Buy
1,364
+1,078
+377% +$595K 0.01% 1286
2020
Q1 		$136K Sell
286
-1,332
-82% -$724K ﹤0.01% 1836
2019
Q4 		$938K Buy
1,618
+1,265
+358% +$888K 0.02% 1199
2019
Q3 		$232K Buy
+353
New +$293K ﹤0.01% 1698
2019
Q2 		– Sell
-58
Closed -$41K – 2608
2019
Q1 		$41K Sell
58
-1,054
-95% -$631K ﹤0.01% 2133
2018
Q4 		$521K Buy
+1,112
New +$717K 0.02% 939
2017
Q1 		– Sell
-55
Closed -$19K – 1901
2016
Q4 		$19K Buy
55
+47
+588% +$15.1K ﹤0.01% 1637
2016
Q3 		$2K Buy
+8
New +$1.73K ﹤0.01% 1667
2016
Q1 		– Sell
-46
Closed -$28K – 1873
2015
Q4 		$28K Sell
46
-393
-90% -$216K ﹤0.01% 1662
2015
Q3 		$226K Buy
+439
New +$294K 0.01% 1401

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cubist Systematic Strategies's TVRD Position: Q4 2023 in Review

Cubist Systematic Strategies sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 1,698 shares — an estimated $103K sold.

Cubist Systematic Strategies first reported a position in TVRD in Q3 2015 and held it in 19 quarters. The position peaked at $2.54M in Q2 2022. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Cubist Systematic Strategies reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,698 Tvardi Therapeutics shares in Q4 2023, an estimated $103K.
  • Cubist Systematic Strategies first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 19 quarters.
  • Cubist Systematic Strategies's Tvardi Therapeutics position peaked at $2.54M in Q2 2022.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Cubist Systematic Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.